Get the Stockscreener App
1.18
2.48%
-0.03
After Hours:
1.22
0.04
+3.39%
Rapt Therapeutics Inc Stock (RAPT) Latest News
A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - US Post News
A stock that deserves closer examination: Solidion Technology Inc (STI) - US Post News
Analytical Lens: Exploring RAPT Therapeutics Inc (RAPT)’s Financial Story Through Ratios - The Dwinnex
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com
SEC Form 424B3 filed by RAPT Therapeutics Inc. - Quantisnow
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - MSN
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Stake Boosted by Barclays PLC - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Sold by Jane Street Group LLC - Defense World
RAPT Therapeutics Plans Phase 2b Trials for RPT904 - TipRanks
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Purchased by Barclays PLC - Defense World
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
RAPT Therapeutics appoints new board chair By Investing.com - Investing.com Nigeria
RAPT Therapeutics appoints new board chair - Investing.com
RAPT Therapeutics, Inc. Announces Board Changes - Marketscreener.com
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors - GlobeNewswire
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $9.56 Average Target Price from Brokerages - MarketBeat
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Rating of “Hold” from Analysts - Defense World
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - Citeline News & Insights
Short Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Grows By 25.5% - MarketBeat
Notable analyst calls this week: FREYR Battery, Apple and ServiceNow among top picks - Seeking Alpha
Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright - Yahoo Finance
RAPT Therapeutics (NASDAQ:RAPT) Upgraded by HC Wainwright to Buy Rating - Defense World
RAPT rockets 180% on licensing deal, $150M private placement (update) - MSN
RAPT Therapeutics Shares Surge After HC Wainwright Upgrade - Marketscreener.com
HC Wainwright & Co. Upgrades RAPT Therapeutics (RAPT) - MSN
RAPT upgraded at H.C. Wainwright on China licensing deal - MSN
RAPT stock upgraded at H.C. Wainwright (RAPT:NASDAQ) - Seeking Alpha
RAPT Therapeutics (NASDAQ:RAPT) Upgraded by HC Wainwright to "Buy" Rating - MarketBeat
RAPT Therapeutics Announces License Agreement and Private Placement - Defense World
RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement - Yahoo Finance
RAPT Therapeutics soars as it looks to raise $150M in private placement - MSN
RAPT Therapeutics sees 113% spike on allergy med licensing deal & private placement - Mugglehead
RAPT Therapeutics, Inc. announced that it expects to receive $149.976555 million in funding from a group of investors - Marketscreener.com
RAPT Therapeutics stock rises following licensing deal with Jemincare By Investing.com - Investing.com Nigeria
RAPT Therapeutics stock rises following licensing deal with Jemincare - Investing.com
Peninsula drugmaker lands $150 million, food allergy drug to fill pipeline holeSan Francisco Business Times - The Business Journals
Why RAPT Therapeutics Stock Gained Over 100% On Monday? - Yahoo Finance
US Stocks Mixed, Dow Tumbles 150 Points - Benzinga
Stock market today: iLearningEngines plunges by 60.44% while Reliance Global Group surged by 231.67% in early trading session - Business Upturn
RAPT Therapeutics secures rights to new allergy antibody - Investing.com
RAPT Therapeutics Partners with Jemincare and Secures Funding - TipRanks
RAPT Therapeutics prices 100M shares at 85c in private placement - TipRanks
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical - GlobeNewswire
RAPT Therapeutics Announces $150 Million Private Placement - GlobeNewswire
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement - The Bakersfield Californian
RAPT Therapeutics Secures $672.5M Deal for Breakthrough Anti-IgE Antibody with Extended Half-Life - StockTitan
Charles Schwab Investment Management Inc. Cuts Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings? - MSN
RAPT Therapeutics stock plunges to 52-week low of $0.92 - Investing.com India
RAPT Therapeutics' SWOT analysis: stock faces challenges amid pipeline setbacks - Investing.com
RAPT Therapeutics stock plunges to 52-week low of $0.92 By Investing.com - Investing.com Nigeria
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):